메인으로

TK Sohn is a CEO of Timefolio Capital. He has strong industrial background with over 13 years of experience in drug discovery. Prior to Timefolio Capital, he had worked for NS Invesment for 6 and a half years as a CEO. TK also held the positions of senior researcher of Dong-A Pharmaceuticals from 2003 to 2016. During his research work for Dong-A, he was instrumental in antibotic molecule called Sivextro approved by FDA back in 2017. He recevied a MS and BS in Pharmacy from Seoul National University.

Ian Heo is a Director for Biotech Investment at Timefolio Capital. He has a industrial background in R&D strategy and early stage business development. Prior to Timefolio Capital, he had worked for NS Investment for 6 and a half years as a Director of healthcare investment team where he had made over 20 investments in the US biotechs. Prior to his time in VC, he was a Associate at Dong-A Pharmaceuticals where he seeked for early stage strategic investment and license opportunities. He received a PharmD at CAU in Korea.

Geon Ko is a Financial Officer at Timefolio Capital. He has an extensive experience over 10 years in corporate finance and financial reporting and operations for venture funds. Prior to joining Timefolio Capital, he was responsible for financial reporting and operations at BNK Venture Capital. He also had worked for POSCO Captial where he was in Finace and Planning team. He received a BS in Sejong University in Korea.

Junbin Seo is a Compliance Officer at Timefolio Capital. He is a Certified Public Accountant in Korea with over 10 years of experience in international tax and risk management. Prior to joining Timefolio Capital, he was a Head of Risk Management team at Korea Investment Priviate Equity. He also had worked for KPMG in International Tax team from 2012 to 2017. He received a BS in Yonsei University in Korea.